this post was submitted on 16 May 2025
7 points (100.0% liked)

Public Health

805 readers
19 users here now

For issues concerning:

🩺 This community has a broader scope so please feel free to discuss. When it may not be clear, leave a comment talking about why something is important.

Related Communities

See the pinned post in the Medical Community Hub for links and descriptions. link ([email protected])

Rules

Given the inherent intersection that these topics have with politics, we encourage thoughtful discussions while also adhering to the mander.xyz instance guidelines.

Try to focus on the scientific aspects and refrain from making overly partisan or inflammatory content

Our aim is to foster a respectful environment where we can delve into the scientific foundations of these topics. Thank you!

founded 2 years ago
MODERATORS
[email protected]
otter
7
Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 YearsA Randomized Clinical Trial (jamanetwork.com)
submitted 1 month ago by otters_raft to c/[email protected]
0 comments fedilink hide all child comments
 

Question Is a multicomponent vaccine against seasonal influenza and SARS-CoV-2 (mRNA-1083) immunogenic and well-tolerated in adults 50 years and older?

**Findings ** In this phase 3 study, mRNA-1083 elicited noninferior immune responses against standard care immunization: licensed standard-dose or high-dose seasonal influenza vaccine (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) coadministered with licensed SARS-CoV-2 (Omicron XBB.1.5) vaccine. The multicomponent vaccine mRNA-1083 had an acceptable tolerability and safety profile.

Meaning mRNA-1083 was demonstrated to be at least as immunogenic as recommended standard care vaccines against both seasonal influenza and COVID-19 and well-tolerated in adults 50 years and older.

no comments (yet)
sorted by: hot top controversial new old
there doesn't seem to be anything here